Welcome to our dedicated page for Equillium news (Ticker: EQ), a resource for investors and traders seeking the latest updates and insights on Equillium stock.
Equillium, Inc. (EQ) is a clinical-stage biotechnology company based in La Jolla, California, dedicated to developing innovative therapies for autoimmune and inflammatory disorders with significant unmet medical needs. Founded in 2017, Equillium has quickly established itself as a frontrunner in the biopharmaceutical industry through its focus on novel treatments that modulate the immune system.
The company’s primary product candidate is itolizumab, a unique monoclonal antibody targeting the immune checkpoint receptor CD6. Itolizumab is currently in advanced clinical trials, specifically a Phase 1b/2 trial for the treatment of acute graft-versus-host disease (aGVHD) and a Phase 1 trial for asthma and lupus nephritis. This promising treatment has shown potential in modulating immune responses and reducing inflammation, providing hope for patients suffering from severe autoimmune conditions.
In addition to itolizumab, Equillium's pipeline includes other groundbreaking therapies. EQ101 is a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15. EQ101 is Phase 2-ready and is expected to begin patient enrollment for an alopecia areata study in the second half of 2022. Another noteworthy drug is EQ102, a cytokine inhibitor that targets IL-15 and IL-21, which is also ready for clinical development and will soon begin enrolling patients in a Phase 1 trial, including those with celiac disease.
Equillium’s commitment to addressing immuno-inflammatory disorders is further demonstrated through its strategic partnerships and collaborations. These alliances have enabled the company to enhance its research capabilities, expedite clinical trials, and bring novel treatments to market more efficiently.
Financially, Equillium is well-positioned to continue its research and development activities. The company has secured funding through various channels, ensuring the advancement of its clinical programs. By focusing on diseases with high unmet needs and leveraging its unique approach to immune modulation, Equillium aims to deliver impactful therapies that improve patient outcomes and quality of life.
For the latest updates on Equillium, Inc., including recent achievements and ongoing projects, keep an eye on their official communications and news releases.
Equillium, Inc. (Nasdaq: EQ) announced its Q3 2020 financial results, highlighting a net loss of $6.6 million, or $(0.31) per share, compared to a loss of $6.0 million, or $(0.35) per share in Q3 2019. The company reported a 100% response rate in cohort 3 and an 80% overall response rate in the EQUATE trial for severe aGVHD. It raised $53.0 million in net proceeds, boosting cash reserves to $90.5 million. Upcoming trials include the Phase 3 EQUINOX for COVID-19 patients, set to start this quarter, with initial data expected mid-2021.
Equillium, Inc. (Nasdaq: EQ) announced that CEO Bruce Steel and CMO Krishna Polu, M.D., will present at two investor conferences in November 2020. The first event is the Stifel 2020 Virtual Healthcare Conference on November 18 at 3:20 PM ET, followed by the Jefferies Virtual London Healthcare Conference on November 19 at 6:10 PM GMT. Live webcasts will be accessible on Equillium's website, with replays available for 30 days. The company is focused on developing its lead product, itolizumab, for various severe autoimmune diseases.
Equillium, a clinical-stage biotechnology company, released positive interim results from its Phase 1b EQUATE trial of itolizumab for treating acute graft-versus-host disease (aGVHD). The trial reported an 80% overall response rate across cohorts, with a 100% complete response in cohort 3. The firm plans to engage the FDA for expedited pathways for itolizumab, which has already received fast track and orphan drug designations. The complete response rate significantly exceeds standard steroid treatments, highlighting the potential of itolizumab as a life-saving therapy for aGVHD patients.
Equillium, Inc. (Nasdaq: EQ) announced promising data on its drug, itolizumab, for treating systemic lupus erythematosus and lupus nephritis. Presented at the 2020 American College of Rheumatology Virtual Convergence on November 7, the studies show that modulating the CD6-ALCAM pathway improved kidney and skin pathology in mouse models. Experts believe this pathway plays a crucial role in autoimmune diseases, suggesting that targeting it could yield effective treatments for lupus nephritis, a condition with no FDA-approved therapies.
Equillium plans to commence a global Phase 3 COVID-19 trial, named EQUINOX, in Q4 2020, following FDA approval. This study will assess the efficacy of itolizumab in hospitalized patients suffering from acute respiratory distress syndrome (ARDS). Enrolling 800 patients, the trial will evaluate recovery rates, mortality, and safety profiles, with initial data expected by mid-2021. The company aims to address critical healthcare needs amid the COVID-19 crisis and anticipates that successful outcomes could support a Biologic License Application (BLA).
Equillium, Inc. (Nasdaq: EQ) announced the presentation of data at the European Respiratory Society International Congress 2020, highlighting the potential of the CD6-ALCAM pathway as a therapeutic target in uncontrolled asthma. The findings show that soluble ALCAM levels were elevated in patients with severe asthma. The company’s ongoing clinical development of itolizumab aims to treat moderate-to-severe uncontrolled asthma, emphasizing its role in modulating immune responses. Current asthma treatments are inadequate for many patients, underlining the need for new therapies.
Equillium, Inc. (Nasdaq: EQ) announces the completion of a pre-IND meeting with the FDA regarding its drug itolizumab for COVID-19 treatment. The FDA provided positive feedback, enabling Equillium to finalize a protocol and plan to submit a U.S. IND application in October 2020. The company aims to start a global Phase 3 clinical trial in Q4 2020. Successful outcomes may support a Biologic License Application. This milestone is crucial for Equillium's plan to treat COVID-19 patients, utilizing itolizumab's unique immune-modulating properties.
Equillium, Inc. (Nasdaq: EQ) has announced that CEO Bruce Steel and CMO Krishna Polu will present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020, at 11 AM ET. The virtual event will feature a live webcast accessible on Equillium's website, with replays available for 30 days. Equillium focuses on developing products for severe autoimmune disorders, with its lead candidate, itolizumab, targeting T cell activity. Itolizumab shows promise in treating cytokine release syndrome in COVID-19 patients and is being explored for other severe conditions.
Equillium, Inc. (Nasdaq: EQ) has completed its underwritten public offering of 5,000,000 shares of common stock, priced at $7.00 per share, raising gross proceeds of $35 million. Joint book-running managers for the offering included Jefferies, SVB Leerink, and Stifel. The offering aims to advance Equillium's clinical development of its monoclonal antibody, itolizumab, which targets severe autoimmune disorders. The SEC has approved the registration statement associated with this offering, and the final prospectus is available on their website.
Equillium, Inc. (Nasdaq: EQ) announced a public offering of 5 million shares at $7.00 per share, with potential proceeds of approximately $35 million. The offering includes a 30-day option for underwriters to purchase an additional 750,000 shares. Funds will support the development of product candidates, potential acquisitions, and general corporate purposes. The closing is anticipated on August 18, 2020. Jefferies, SVB Leerink, and Stifel serve as joint book-running managers.
FAQ
What is the current stock price of Equillium (EQ)?
What is the market cap of Equillium (EQ)?
What does Equillium, Inc. specialize in?
What is itolizumab?
What other products are in Equillium's pipeline?
Where is Equillium, Inc. headquartered?
When was Equillium, Inc. founded?
What are the current clinical trials for itolizumab?
What is the focus of EQ101?
What conditions is EQ102 targeting?
How is Equillium funded?
How can I stay updated on Equillium, Inc.'s latest news?
